MDCO News and Press, The Medicines Company From 04/30/19

Antibiotic resistance is a growing global public health emergency. Melinta Therapeutics ( MLNT ) has decided to take up the critical mission of overcoming antibiotic resistance with their broad spectrum antibiotic portfolio. Unfortunately, the market doesn’t see the opportunity in addre...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

Aratana Therapeutics (NASDAQ: PETX ) +37%  on Elanco takeover . More news on: Aratana Therapeutics, Inc., Regional Health Properties, Inc., Reebonz Holding Limited, Stocks on the move, Read more ...

Aurora Cannabis (NYSE: ACB ) initiated with Buy rating and C$16.50 (35% upside) price target at Desjardins. Shares up  1%  premarket on the heels of its license deal with EnWave. More news on: Aurora Cannabis Inc., Gilead Sciences, Inc., Tocagen Inc., Healthcare stocks news, Stoc...

The Medicines Company (MDCO) Q1 2019 Earnings Conference Call April 25, 2019 8:30 AM Company Participants Krishna Gorti - VP, IR Mark Timney - CEO Christopher Visioli - CFO Peter Wijngaard - CDO Conference Call Participants Paul Choi - Goldman Sachs Tazeen Ahmed - Bank ...

Medicines ( MDCO ) Q1 results : Revenues: $0; R&D Expense: $27M (-33.2%); SG&A: $17M (-41.4%); Net Loss: ($59.9M) (+29.4%); Loss Per Share: ($0.80) (+30.4%); Non-GAAP Net Loss: ($46M) (+18.4%); Non-GAAP Loss Per Share: ($0.62) (+18.4%). More news on: The Medicines Company, Healthc...

Inclisiran’s unique profile, vast global market opportunity and long-dated exclusivity set the stage for potentially significant shareholder value creation Independent Data Monitoring Committee recommends continuation of inclisiran Phase 3 clinical trials after sixth un-blind...

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, April 25, 2019 at 8:30 a.m. EDT to discuss its first quarter 2019 financial results and operational developments. The conference call may be accessed by telephone as follows: U.S./Canada: (...

Respect is tendered with pleasure only where it is not exacted .” - Anne Robert Jacques Turgot Today, we take a look at a concern that is transforming itself with a new direction and CEO. The stock is well off its highs of last summer and seeing a large amount of recent insider buy...

The following slide deck was published by The Medicines Company in conjunction with this Read more ...